Table 3.
Results for wipe extraction recovery studies
| Analyte/trial | Type | Number of concentrations tested |
Recovery range (%) |
Mean recovery and RSD (%) |
|---|---|---|---|---|
| Cyclophosphamide | ||||
| Trial 1 | Spiked wipes | 7 | 91.9–112.6 | 100.3 (8.1) |
| Trial 2 | LCS | 5 | 83.1–108.1 | 95.3 (10.2) |
| Spiked wipes | 7 | 86.7–102.7 | 96.1 (6.5) | |
| Trial 3 | LCS | 5 | 86.4–106.1 | 97.0 (7.0) |
| Spiked wipes | 7 | 98.0–106.6 | 107.4 (9.6) | |
| Ifosfamide | ||||
| Trial 1 | LCS | 6 | 96.9–113.4 | 103.7 (2.9) |
| Spiked wipes | 7 | 97.3–117.6 | 105.5 (7.8) | |
| Trial 2 | LCS | 7 | 96.9–104.1 | 101.3 (2.9) |
| Spiked wipes | 7 | 83.2–118.5 | 100.4 (12.1) | |
| Doxorubicin | ||||
| Trial 1 | LCS | 5 | 89.1–103.1 | 95.6 (5.2) |
| Spiked wipes | 7 | 55.1–89.1 | 74.2 (13.6) | |
| Trial 2 | LCS | 5 | 88.2–100.2 | 94.2 (5.8) |
| Spiked wipes | 6 | 66.1–74.9 | 72.4 (6.0) | |
| Trial 3 | LCS | 5 | 84.2–96.9 | 90.6 (5.9) |
| Spiked wipes | 6 | 66.2–83.2 | 74.3 (8.3) | |
| Paclitaxel | ||||
| Trial 1 | LCS | 6 | 107.6–122.4 | 115.4 (6.7) |
| Spiked wipes | 6 | 100.2–133.0 | 115.6 (6.3) | |
| Trial 2 | LCS | 6 | 104.6–123.5 | 121.7 (8.8) |
| Spiked wipes | 6 | 98.1–134.9 | 118.8 (9.4) | |
| 5-Fluorouracil | ||||
| CCVBVNA | 1 | 95.6–105.2 | 100.2 (3.0) | |
| LCS | 6 | 91.8–98.3 | 94.8 (2.7) | |
| Spiked wipes | 6 | 91.7–100.5 | 98.5 (3.9) |
LCS = Laboratory control samples. Each LCS concentration level was run once with the indicated set of wipe sample extracts and the range of individual recoveries and their mean and RSD are reported. CCVBVNA = Continuing calibration verification standard: 10 ng/mL FU run periodically during the sample queue. Three spiked wipe samples were prepared for each target concentration. Average recovery for each concentration was determined and the recovery range of these values is reported, along with the mean and RSD of these averages.
Note: No LCS accompanied the first trial of spiked wipe recovery for cyclophosphamide.